Cannabidiol
Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
CBDLoading study record…
Loading study record…
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD. The study has been powered to detect a clinically significant reduction in Movement Disorder Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores. This is a 1:1 parallel, double-blind, randomized controlled trial (RCT) with 60 participants. The investigators will be recruiting up to 75 participants; the goal is to have 60 participants (30 in CBD group and 30 in placebo group) complete the study. The study drug is obtained from the National Institute on Drug Abuse (NIDA).
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2024-07-23
What this record can show
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Registry facts
Persons with PD have progressive disabling tremor, slowness, stiffness, balance impairment, cognitive deficits, psychiatric symptoms, autonomic dysfunction, fatigue and insomnia. Tremor may interfere with necessary daily and work functions. The disorder affects approximately seven million people globally. The total economic cost in the US is around 23 billion dollars. In addition to economic costs, PD reduces quality of life of those affected and their caregivers. Cognitive impairment is a common feature and ranges from delayed recall in early stages to global dementia in up to 80% at end stage. PD with dementia has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Community-based studies have estimated the point prevalence for dementia in PD to be 28% and 44%. Depression, anxiety and psychosis are also common and are particularly disabling in PD, even at the earliest stages. These symptoms have important consequences for quality of life and daily functioning, are associated with increased carer burden and risk for nursing home admission. Anxiety affects up to 40% of patients with PD, and may predate motor symptoms by several years. The most common anxiety disorders in PD are panic attacks (often during off-periods), generalized anxiety disorder, and simple and social phobias. Psychotic symptoms vary in frequency according to the definition used. If mild forms are included, these affect up to 50% of patients. Visual hallucinations are the most common type. However, hallucinations occur in all sensory domains and delusions of various types are also relatively common. The impact of psychosis is substantial in that it is associated with dementia, depression, earlier mortality, greater caregiver strain, and nursing home placement. Thus, it is crucial to treat these symptoms in order to optimize the management of PD patients. Generally, however, current therapies are inadequate. Medications have improved the prognosis of PD, but also have problematic adverse effects. Since treatment of PD is often unsatisfactory and since cannabis has recently become legal and readily available in Colorado, persons with PD have been trying it. Patients have heard from the internet, support groups and other sources that marijuana is helpful. Most are doing so on their own, without the supervision or even knowledge of their neurologist. In a survey conducted in the spring of 2014 in University of Colorado Hospital Movement Disorders clinic about 5% of 207 PD patients, average age 69, reported using cannabis. In another study reported that 25% of PD patients had taken cannabis in the General University Hospital in Prague. In the investigators clinics, about 30% of the PD patients have asked doctors during their clinic visits over the past 6 months about cannabis. In an anonymous web-based survey, 72% PD patients reported current or past using medical cannabis, and 48% reducing prescription medication since beginning cannabis use. PD mostly affects the elderly, and affected persons often have cognitive, psychiatric and motor problems, such as being prone to falling. Cannabis is well documented to cause psychosis, anxiety, slowness and incoordination. Studies have also shown that chronic users have structural and functional Central Nervous System (CNS) alterations. Thus cannabis is expected to be risky in persons with PD. Further, there are many components of cannabis, and the cannabis preparations being sold in Colorado vary widely in composition. There are no definitive data regarding the benefits and risks in of these various preparations in PD. Studies on safety and efficacy are greatly needed to protect this fragile Colorado population. Human trials report that CBD decreases anxiety and causes sedation in healthy individuals, decreases psychotic symptoms in schizophrenia and PD, and improves motor and non-motor symptoms and alleviates levodopa-induced dyskinesia in PD. Given the current literature regarding CBD: possible neuroprotective effect, good tolerability, anxiolytic and antipsychotic effects and general lack of information in PD, including its effect on tremor, the investigators feel that it is important to study its use in PD further. The investigators hypothesized that it would reduce tremor, anxiety and psychosis, and would be well tolerated in PD. The Specific Aims are: Primary Specific Aim: To evaluate the efficacy of CBD on motor symptoms in PD, specifically on the motor section of the Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS). Secondary Specific Aim: To assess the safety and tolerability of CBD in PD, and to examine the effect of CBD on severity \& duration of intractable tremor, night-time sleep, rigidity, emotional dyscontrol, anxiety and pain in PD. Exploratory Analyses: To study the efficacy of CBD on cognition, psychosis, sleep, daytime sleepiness, mood, fatigue, impulsivity, bladder function, other motor and non-motor PD signs, restless legs syndrome and Rapid Eye Movement (REM) sleep behavior disorder and quality of life. To explore the effect of CBD on plasma levels in PD. The study is a randomized, placebo controlled, double-blind parallel design with two treatment arms, each of approximately 2-3 weeks duration. In the 2-3 week treatment phase participants will start study drug and titrate up to the maximum tolerated or targeted dose (2.5 mg/kg/day of CBD). Each participant will have a screening visit, baseline visit within 3 weeks, 1 liver function monitoring visits on 3rd to 5th day of 2.5 mg/kg/day, 2 dose assessment visit (1.25 mg/kg/day and 2.5 mg/kg/day), and a safety visit (6 visits total). Participants will be evaluated on the 3rd to 5th day at each dose level for monitoring liver function and adverse events, as well as changes in medical history and concomitant medications. Participants are called 3 days and 1 week after stopping the study drug to check for signs of withdrawal.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
CBDSubjects randomized to this arm will receive Placebo
Source-reported results
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Movement Disorders Society-Unified Parkinson's disease rating scale(MDS UPDRS) Part III assesses the motor signs of PD. There are 33 scores based on 18 items, several with right, left or other body distribution scores.Each question is anchored with five responses that are linked to commonly accepted clinical terms: 0=normal, 1=slight, 2=mild, 3=moderate, and 4=severe. The possible change may be the scores of the total 33 scores. Scores ranges 0 -132. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -4.5714 | -8.1126 to -1.0302 |
| Placebo | 30 | -2.7665 | -4.9213 to -0.6118 |
Adverse events (AEs) are collected at each dose level. AEs collection include Serious Adverse Events (SAE), withdrawal symptoms and common AEs. SAE is an undesirable medical occurrence that results in death, or life-threatening, or inpatient hospitalization or prolongation of existing hospitalization or significant disability or incapacity or in a congenital anomaly/birth defect. Withdrawal and common AEs include headache, anxiety, nausea/vomiting, tremor, chills, decreased concentration, increased concentration, agitation, irritability, sleep disturbances, mood changes, somnolence, fatigue, anorexia, appetite changes, weight loss or gain, diarrhea, convulsion, abdominal pain, weakness, fever and other unexpected AEs. All of the these AEs will be recorded and counted.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 26 | - |
| Placebo | 30 | 25 | - |
Liver function tests will be performed and evaluated at each clinic visit from baseline through 3 weeks. The result is reported as the number of participants that had a clinically significant change in the values of the liver function test, including aspartate aminotransferase (AST), Alanine transaminase (ALT), Gamma-glutamyl transferase (GGT), Alkaline phosphatase (Alk Phos), Total Bilirubin (TB).
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0 | - |
| Placebo | 30 | 0 | - |
Liver function impairment will be evaluated and then related to adverse events and documented at each clinic visit. The change may be the frequency and severity of liver function impairment related AEs, including nausea/vomiting, diarrhea, abdominal pain, fatigue, weakness, chills, appetite changes, weight loss or gain, fever, etc.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution · nausea | 31 | 6 | - |
| Placebo · nausea | 30 | 3 | - |
| CBD Cannabis Extract Oral Solution · diarrhea | 31 | 2 | - |
| Placebo · diarrhea | 30 | 4 | - |
| CBD Cannabis Extract Oral Solution · fatigue | 31 | 10 | - |
| Placebo · fatigue | 30 | 6 | - |
| CBD Cannabis Extract Oral Solution · abdominal pain | 31 | 1 | - |
| Placebo · abdominal pain | 30 | 3 | - |
| CBD Cannabis Extract Oral Solution · anorexia | 31 | 2 | - |
| Placebo · anorexia | 30 | 3 | - |
| CBD Cannabis Extract Oral Solution · weight loss | 31 | 1 | - |
| Placebo · weight loss | 30 | 2 | - |
| CBD Cannabis Extract Oral Solution · not applicable | 31 | 9 | - |
| Placebo · not applicable | 30 | 9 | - |
Standing systolic blood pressure measurements will be assessed through 3 weeks. The change may be the value of systolic blood pressure.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | -5.4145 | -11.4569 to 0.6279 |
| Placebo | 30 | -0.9891 | -6.4615 to 4.4833 |
The change may be Heart rate (beat/minute) while standing.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | 0.9459 | -3.1640 to 5.0559 |
| Placebo | 30 | 0.6326 | -2.1185 to 3.3838 |
The change may be weight in kilograms or lbs.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | 0.07389 | -0.2163 to 0.3641 |
| Placebo | 30 | -0.07658 | -0.4177 to 0.2645 |
The change may be temperature in Fahrenheit degree
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | -0.3069 | -0.6335 to 0.01972 |
| Placebo | 30 | -0.1882 | -0.5579 to 0.1816 |
The result is reported as the number of participants that had a clinically significant change in the physical exam findings, including allergic immunologic, cardiovascular, constitutional symptoms, ENT, endocrine, eyes, gastrointestinal, genitourinary, hematologic, integumentary, musculoskeletal, neurological, psychiatric, respiratory and other symptoms clinical significant findings.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0 | - |
| Placebo | 30 | 0 | - |
The result is reported as the number of participants that had a clinically significant change in the general neurological exam clinical significant findings, including cranial nerves, motor strength, sensation, reflexes, gait, and other movements.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0 | - |
| Placebo | 30 | 0 | - |
The result is reported as the number of participants that had a clinically significant change in the EKG.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0 | - |
| Placebo | 30 | 0 | - |
The result is reported as the number of participants that had a clinically significant change in the values of Hematology parameters, including RBC, WBC, HB, PLT, et al.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0 | - |
| Placebo | 30 | 0 | - |
The result is reported as the number of participants that had a clinically significant change in the values of the Chemistry profile, including BUN, CR, Electrolyte, glucose, liver function, etc.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0 | - |
| Placebo | 30 | 0 | - |
Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild cognitive dysfunction. The change may be the scores of MoCA, which is ranging from 0-30. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.8341 | -1.7743 to 0.1062 |
| Placebo | 30 | -0.5000 | -1.3489 to 0.3489 |
The change may be the scores of Wechsler test for Adult Reading. Wechsler Test of Adult Reading (WTAR) - Word reading tests are an established method of establishing a premorbid estimate of verbal intellectual functioning, which will serve as an estimate of premorbid cognitive reserve. The WTAR comprises 50 words with irregular pronunciations that participants read aloud. The raw score can be transformed to an age-adjusted standard score, which is used to predict IQ (M = 100; SD = 15). Scores higher means better.
Population: Out of the total study population, 25 participants took the cognitive test from CBD group, and 26 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 25 | 0.4421 | -1.6349 to 2.5192 |
| Placebo | 26 | -1.4931 | -3.0859 to 0.09972 |
The change are the scores of Grooved Pegboard Test for the dominant affected hand. Manipulative dexterity, including finger speed, is assessed. Scoring is the time it took the participant to complete the task. Start the clock once the participant starts and stop it once the task has been completed. If after five minutes the participant has not completed the pegboard, stop the participant. The score the higher the worse.
Population: Out of the total study population, 15 participants performed the cognitive test from CBD group, and 14 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 15 | 5.3406 | -12.2701 to 22.9514 |
| Placebo | 14 | -14.3454 | -27.0367 to -1.6540 |
The change may be the scores of Intellectual functioning estimate, Symbol digit modalities test (SDMT). The SDMT is a measure of processing speed and working memory that has proven to be sensitive to cognitive impairment in MS that has both oral and written trials (only the oral trial will be administered given the anticipated difficulty patients will have with tremor). Participants are presented with a key at the top of a page pairing unique symbols with single digits. Participants are required to provide the correct digit with symbols that are presented on the rest of the page. The score is the number of correctly coded items from 0-110. The number of correct responses provided in 90 seconds on the oral trial is recorded. Scores range 0-110 items. The higher the score the better.
Population: Out of the total study population, 29 participants performed the cognitive test from CBD group, and 29 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 29 | 0.6143 | -2.0546 to 3.2832 |
| Placebo | 29 | 3.8357 | 1.1306 to 6.5408 |
The change may be the scores of Intellectual functioning estimate, Paced auditory serial addition test. Paced Auditory Serial Addition Test (PASAT) - The PASAT is a more complex measure of processing speed and working memory in which a series of digits is presented to participants at varying intervals (i.e., 2 seconds, 3 seconds). Participants must add each digit to the immediately preceding digit for the duration of each trial. The number of correct responses for each trial is recorded. The score for the PASAT is the total number correct out of 60 possible answers. The higher, the better.
Population: Out of the total study population, 27 participants performed the cognitive test from CBD group, and 25 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 27 | 6.9653 | -0.04668 to 13.9773 |
| Placebo | 25 | 11.9489 | 5.5760 to 18.3219 |
The change may be the scores of Intellectual functioning estimate, Controlled oral word association test (COWAT). The COWAT is a measure of speeded verbal fluency and word retrieval in which participants are asked to say as many words as they can that begin with each of three letters for 60 seconds. The total number of words generated across all three trials is recorded. The higher, the better.
Population: Out of the total study population, 29 participants performed the cognitive test from CBD group, and 29 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 29 | 3.1675 | 1.0881 to 5.2470 |
| Placebo | 29 | 2.5916 | -0.8430 to 6.0262 |
The change may be the scores of Intellectual functioning estimate, Hopkins verbal learning test-revised. Hopkins Verbal Learning Test-Revised (HVLT-R) - The HVLT-R is a measure of verbal learning and memory in which participants are asked to learn a 12-item word list over three trials (total immediate learning). When scoring, the three leaning trials are combined to calculate a total recall score. Score ranges 0-36. The higher, the better. The outcoe measure is reporting the change from baseline in the total leaning score across all three trials.
Population: Out of the total study population, 26 participants performed the cognitive test from CBD group, and 25 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 26 | -2.03 | 1.06 |
| Placebo | 25 | -1.30 | 1.15 |
Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed recall trial. The participant is asked to recall as many words as they can 20-25 minutes after being presented the word list. The range is 0-12; the higher, the better.
Population: Out of the total study population, 26 participants performed the cognitive test from CBD group, and 25 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 26 | -1.16 | 0.60 |
| Placebo | 25 | -0.28 | 0.26 |
The change may be the scores of Intellectual functioning estimate, Hopkins verbal learning test-revised. Hopkins Verbal Learning Test-Revised (HVLT-R) is a measure of verbal learning and memory in which participants are asked to learn a 12-item word list over three trials (total immediate learning). Delayed recognition trials is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, and 6 semantically unrelated. Retention % = percentage retained or delayed recall divided by better score on trial 2 or 3. Range 0-1. The higher, the better.
Population: Out of the total study population, 26 participants performed the cognitive test from CBD group, and 25 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 26 | 0.54 | 0.48 |
| Placebo | 25 | 0.55 | 0.27 |
The change may be the scores of Intellectual functioning estimate, Judgment of line orientation. Judgment of Line Orientation (JOLO) - The JOLO is test of visuospatial functioning which measures a person's ability to match the angle and orientation of lines in space. Patients are asked to match two angled lines to a set of 11 lines that are arranged in a semicircle and separated 18 degrees from each other. Score ranges 0-30. The higher, the better.
Population: Out of the total study population, 26 participants performed the cognitive test from CBD group, and 25 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 26 | 0.1367 | -1.0173 to 1.2907 |
| Placebo | 25 | -1.1626 | -2.6697 to 0.3446 |
The change may be the scores of Semantic verbal fluency. Semantic Verbal Fluency - Semantic Verbal fluency is a measure of speeded verbal fluency and word retrieval in which participants are asked to say as many animal names/fruits and vegetables for 60 seconds. The total number of words generated across all three trials is recorded. The higher the score is, the better.
Population: Out of the total study population, 29 participants performed the cognitive test from CBD group, and 29 from placebo group.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 29 | 0.7153 | -0.7948 to 2.2253 |
| Placebo | 29 | 2.4672 | 0.8614 to 4.0729 |
Comprised of 8 items which has five response options. Anxiety short form - is component of the Neurol-QOL (Quality of Life in Neurological Disorders) Measurement System, which is a collaborative effort of the National Institute of Neurological Disorders and Stroke and a number of partnering institutions. This measurement system was designed to be responsive to the needs of researchers in a variety of neurological disorders and to facilitate comparisons of data across clinical trials in different diseases. The short form is comprised of eight items that were selected from the respective item bank. Items have five response options (e.g., 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always). Respondents generally can answer five questions per minute. The change may be the total scores of the 8 items. Higher values represent a worse outcome. Scores range 8-40.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -2.1001 | -3.6111 to -0.5891 |
| Placebo | 30 | -3.4533 | -4.8327 to -2.0740 |
Valid and reliable scale to provide a means of assessing neuropsychiatric symptoms and psychopathology of patients. The change may be the scores of NPI. Neuropsychiatric Inventory (NPI) - is a valid and reliable scale. It was developed to provide a means of assessing neuropsychiatric symptoms and psychopathology of patients with Alzheimer's disease and other neurodegenerative disorders. It has proven to be sensitive to change and has been employed to capture treatment related behavioral. The NPI is administered to a caregiver/significant other who has detailed knowledge of the participant's behavior. Higher values represent a worse outcome. Score ranges 0-12.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | -0.3000 | -0.9611 to 0.3611 |
| Placebo | 30 | -1.2667 | -2.7392 to 0.2058 |
Scales for Outcomes in Parkinson's disease (SCOPA)sleep - is a valid, reliable, short scale for assessing daytime sleepiness (DS) and nighttime sleep problems (NS) in patients with PD. The DS sub scale evaluates daytime sleepiness and includes six items with four response options, ranging from 0 (never) to 3 (often). The score ranges 0-18. The higher the worse. The other
Population: 31 patients from CBD group and 30 from placebo group conducted the SCOPA DS scales.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.5280 | -1.2572 to 0.2012 |
| Placebo | 30 | -0.2667 | -1.0365 to 0.5031 |
Comprised of 8 items which item has five response options. Depression short form - is a component of the Neurol-QOL (Quality of Life in Neurological Disorders) Measurement System, which is a collaborative effort of the National Institute of Neurological Disorders and Stroke and a number of partnering institutions. This measurement system was designed to be responsive to the needs of researchers in a variety of neurological disorders and to facilitate comparisons of data across clinical trials in different diseases. The short form is comprised of eight items that were selected from the respective item bank. Items have five response options (e.g., 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always). Respondents generally can answer five questions per minute. The change may be the scores of the total 8 items. Score ranges 0-40. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | -1.7300 | -3.9531 to 0.4931 |
| Placebo | 30 | -2.0367 | -4.1183 to 0.04500 |
Comprised of 8 items which item has 5 response options. Emotional and behavioral dyscontrol short form - is a component of the Neurol-QOL Measurement System, which is a collaborative effort of the National Institute of Neurological Disorders and Stroke and a number of partnering institutions. This measurement system was designed to be responsive to the needs of researchers in a variety of neurological disorders and to facilitate comparisons of data across clinical trials in different diseases. The short form is comprised of eight items that were selected from the respective item bank. Items have five response options (e.g., 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always). Respondents generally can answer five questions per minute. The change may be the total scores of the 8 items. Score ranges 0-40. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -3.9870 | -6.3219 to -1.6522 |
| Placebo | 30 | -4.2733 | -6.8021 to -1.7445 |
Is a quick and easy way to assess how the participant is feeling. The change may be the scores of the scale 3 hours after dosing compared to pre-dosing. Stanford Sleepiness Scale (SSS): The Stanford Sleepiness Scale is a quick and easy way to assess how alert the participant is feeling. SSS is validated and probably the most widely used instrument for the assessment of participant's sleepiness. Score ranges 0-7. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0.2903 | -0.1380 to 0.7187 |
| Placebo | 30 | -0.03333 | -0.3298 to 0.2631 |
Assess how much a person hurts. The change may be the score of the short form. Pain Intensity 3a short form - components of the Patient Reported Outcome Measurement Information System (PROMIS), which was developed by the NIH to provide a standardized metric for measuring physical, mental, and social health across chronic diseases. PROMIS instruments were developed using item response theory and have been tested in more than 20,000 individuals drawn from the general US population. The Pain Intensity instrument assesses how much a person hurts. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Each question has five response options ranging in value from one to five. Score ranges 0-15. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -3.1209 | -4.9451 to -1.2968 |
| Placebo | 30 | -2.6169 | -4.8111 to -0.4226 |
Self-reported consequences of pain on relevant aspects of one's life. The change may be the scores of the short form. The Pain Interference instrument measures the self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Each question has five response options ranging in value from one to five. Score ranges 0-20. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.1543 | -2.1498 to 1.8412 |
| Placebo | 30 | -2.7701 | -4.8473 to -0.6929 |
Self-report 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity. The change may be the total scores of the 9 items, ranging from 9-63. Higher values represent worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 1.4224 | -2.2727 to 5.1175 |
| Placebo | 30 | -1.3667 | -4.3254 to 1.5920 |
Movement Disorder Society Unified Parkinson Disease Rating Scale. There are four parts, non-motor experiences of daily living, motor experiences of daily living, motor examination, and motor complications. The change may be the total scores of the four parts. Total score ranges 0-260. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -6.2798 | -11.5293 to -1.0303 |
| Placebo | 30 | -7.2333 | -10.5756 to -3.8911 |
To evaluate involuntary movements often associated with treated PD. The change may be the total scores of the scale, including historical sub-score (0-60) and objective sub-score (0-44). The total score is historical sub score plus objective sub score, ranged from 0- 104. Higher values represent a worse outcome.
Population: In CBD group, 31 patients at baseline and 29 patients at 2.5 mg/kg/day were testes. In Placebo group, 30 at baseline and 28 at 2.5 mg/kg/day were tested.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 1.4704 | -1.4078 to 4.3487 |
| Placebo | 30 | -1.4270 | -3.2753 to 0.4214 |
The Timed Up \& Go (TUG) test is a physical performance measure in which the ability to rise up from a seated chair position, walk 3m, turn, walk back, and sit down is timed. This measure is useful in an outpatient setting, because it requires only a few minutes, is easy to administer, and requires little equipment. Importantly, the TUG test is highly correlated with functional mobility, gait speed, and falls in older adults. The change may be the time duration (seconds) of performing the task. The higher, the worse.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | -0.5409 | -1.3780 to 0.2962 |
| Placebo | 30 | -0.5922 | -1.0932 to -0.09113 |
International restless legs syndrome (IRLS) study group rating scale for restless legs syndrome. The change may be the scores of the IRLS, ranged from 0-40. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -1.2366 | -3.3440 to 0.8709 |
| Placebo | 30 | -0.5667 | -2.2772 to 1.1439 |
REM sleep behavior disorder screening questionnaire (RBDSQ). The change may be the total scores of RBDSQ. REM sleep behavior disorder screening questionnaire (RBDSQ) - is a 10-item, patient self-rating instrument assessing the participant's sleep behavior with short questions that have to be answered by either "yes" or "no". Items 1 to 4 address the frequency and content of dreams and their relationship to nocturnal movements and behavior. Item 5 asks about self-injuries and injuries of the bed partner. Item 6 consists of four sub items assessing nocturnal motor behavior more specifically, e.g., questions about nocturnal vocalization, sudden limb movements, complex movements, or bedding items that fell down. Items 7 and 8 deal with nocturnal awakenings. Item 9 focuses on disturbed sleep in general and item 10 on the presence of any neurological disorder. The maximum total score of the RBDSQ is 13 points. Score ranges 0-13 points. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.4692 | -1.0392 to 0.1009 |
| Placebo | 30 | -0.3333 | -1.0095 to 0.3429 |
A validated self-administered questionnaire consisting of 7 questions on a 5-point Likert scale. The change may be the scores of the scale, ranged from 0-35. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.09605 | -1.0385 to 0.8464 |
| Placebo | 30 | 0 | -1.2663 to 1.2663 |
A reliable valid responsive acceptable and feasible tool for assessment of quality of life in PD, including 39 multiple-choice items covering 8 dimensions: mobility (#1-10), activities of daily living (#11-16), emotional well-being (#17-22), stigma (#23-26), social support (#27-29), cognition (#30-33), communication (#34-36), and bodily discomfort (#37-39). 5-point ordinal scoring system: 0=never, 1= occasionally, 2=sometimes, 3=often, 4=always. The change may be the total scores of PDQ-39, ranged from 0-156. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -4.8005 | -10.0155 to 0.4145 |
| Placebo | 30 | -4.4788 | -8.6298 to -0.3278 |
Consists of 2 pages-the EuroQol-5 Dimension-5 level (EQ-5D-5L) descriptive system and the EuroQol (EQ) Visual analogue scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS records the patient's self-rated health on a vertical visual analogue-scale, where the endpoints are labelled the best health you can imagine and the worst health you can imagine. The change may be the scales of EQ-5D. Score ranges 11111-55555. The higher, the worse.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 0.05364 | 0.009875 to 0.09741 |
| Placebo | 30 | 0.02467 | -0.01451 to 0.06384 |
Difference in Proportion of participants that discontinue the study due to study drug intolerance. The change may be the number of patients dropped out.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | 1 | - |
| Placebo | 30 | 0 | - |
Rest tremor amplitude and constancy of rest tremor scores in MDS UPDRS. The change may be the sum scores of 3.17 and 3.18. Score ranged from 0-24. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -1.1570 | -2.0377 to -0.2763 |
| Placebo | 30 | -0.1000 | -0.7625 to 0.5625 |
Patient's tremor experience. The change may be the scores of item 2.10. Score ranged from 0-4. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.2280 | -0.4929 to 0.0368 |
| Placebo | 30 | -0.100 | -0.3008 to 0.1008 |
Postural tremor of the hands and kinetic tremor of the hand. The change may be the sum scores of item 3.15 and 3.16. Score ranged from 0-16. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.4291 | -0.9259 to 0.0677 |
| Placebo | 30 | -0.6667 | -1.1317 to -0.2016 |
Rigidity sub scores in MDS UPDRS. The change may be the sub scores of rigidity related item in MDS UPDRS (item 3.3). Score ranged from 0-20. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.3742 | -1.6096 to 0.8612 |
| Placebo | 30 | -0.6030 | -1.5951 to 0.3891 |
Bradykinesia sub scores in MDS UPDRS. The change may be the sub scores of bradykinesia related items in MDS UPDRS, including items 3.4-3.8, and 3.14. The scores ranged from 0-44. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -1.6787 | -3.6134 to 0.2560 |
| Placebo | 30 | -0.8666 | -2.6253 to 0.8921 |
Axial sub scores in MDS UPDRS. The change may be the sub scores of axial related items in MDS UPDRS, including items 3.9, 3.13, 3.10, 3.11, and 3.12. The sub scores ranged from 0-20. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.2919 | -0.8076 to 0.2237 |
| Placebo | 30 | -0.2667 | -0.8275 to 0.2941 |
Bulbar sub scores in MDS UPDRS (item 3.1 and 3.2). The change may be the sub scores of bulbar related items in MDS UPDRS, ranged from 0-8. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.3376 | -0.8015 to 0.1263 |
| Placebo | 30 | -0.03333 | -0.6754 to 0.6088 |
Insomnia Severity Index (ISI): ISI is a verified seven-item self-report questionnaire assessing the nature, severity, and impact of insomnia. A five-point Likert scale is used to rate each item (e.g., 0=no problem; 4=very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28). A total score ranging from 0 to 28. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -1.6982 | -2.8162 to -0.5803 |
| Placebo | 30 | -1.6333 | -2.7246 to -0.5421 |
To measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. The change may be the total scores, ranged from 0 to 42. The higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.8226 | -1.7676 to 0.1225 |
| Placebo | 30 | -1.5000 | -2.1722 to -0.8278 |
Dermatology quality of life index. The change may be the scores of the questionnaire. The scoring of each question is as follows: very much=3, a lot =2, a little=1, not at all=0, not relevant =0. Question 7, prevented work or studying =3. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.1763 | -0.7571 to 0.4044 |
| Placebo | 30 | 0.1000 | -0.3343 to 0.5343 |
Dermatology photography evaluation. The change in number of participants with a presence of seborrheic dermatitis from baseline to final visit. Dermatology photography: take a picture of the central face, as this is the most common area of seborrhea, and send it, with appropriate privacy safeguards, to dermatologists, Dr. Robert Dellavalle, MD., and Dr. Andrea Steel.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 29 | 2 | - |
| Placebo | 29 | 3 | - |
Validated 30-item scale for the assessment of NMS in PD. Each symptom scored with respect to severity (0=none, 1=mild, 2=moderate, 3=severe), frequency (1=rarely, 2=often, 3=frequent, 4=very frequent). Each NMSS item score is calculated by multiplying the severity and frequency score. The final score is the sum of the total 30-item scores. The change may be the total scores of NMSS, ranged from 0 to 360. The higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -5.8652 | -11.6281 to -0.1023 |
| Placebo | 30 | -5.0333 | -8.9647 to -1.1020 |
Scales for Outcomes in Parkinson's disease (SCOPA) sleep DS subscale is a valid, reliable, short scale for assessing daytime sleep problems (DS) in patients with PD. The sub scale includes six items with four response options, ranging from 0 (never) to 3 (often). The score ranges 0-18. The higher the worse.
Population: 31 patients from CBD group and 30 from placebo group conducted the SCOPA DS scales.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -0.5280 | 0.3575 |
| Placebo | 30 | -0.2667 | 0.3769 |
Scales for Outcomes in Parkinson's disease (SCOPA) sleep NS subscale - is a valid, reliable, short scale for assessing nighttime sleep problems (NS) in patients with PD. The NS sub scale includes five items with four response options, ranging from 0 (never) to 3 (often). The score ranges 0-15. The higher the worse.
Population: 31 patients from CBD group and 30 from placebo group conducted the SCOPA NS scales.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 31 | -1.2066 | 0.5075 |
| Placebo | 30 | -1.2333 | 0.4074 |
Modified Dysfunctional Beliefs and Attitudes about Sleep Questionnaire (DBAS-16): A validated self-reported questionnaire designed to identify and assess various sleep/insomnia-related cognitions (e.g., beliefs, attitudes, expectations, appraisals, attributions). range is 0-160; the higher numbers are worse.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | -2.70 | 3.40 |
| Placebo | 30 | -4.57 | 3.30 |
WASO, the total number of minutes that a person is awake after having initially fallen asleep; higher numbers are worse.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 21 | -48.89 | -80.25 to -17.53 |
| Placebo | 25 | -1.97 | -53.29 to 49.35 |
Interleukin 6 is an inflammatory cytokine, and is measured in the blood. Whole bold was collected into tubes containing anticoagulant; tubes were inverted gently 3-4 times. Blood was allowed to clot at room temperature for 30 to 45 min, centrifuged at 1,000 x g for 15 min at 4°C and serum was transferred to a clean polypropylene tube. To completely remove platelets and precipitates, the tubes were centrifuge again at 10,000 x g for 10 min at 4°C. Processed samples were stored at -80°F, and cytokine levels measured using the Bio-Plex ProTM Human Cytokine Assay.
Population: PD participants who took either cannabidiol cannabis extract oral solution or placebo.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 17 | 2.99 | 0.61 to 14.66 |
| Placebo | 19 | 1.59 | 0.33 to 7.66 |
To measure severity of symptoms and support a diagnosis of impulse control disorders and related disorders in PD. The result is the difference of the change of the total scores of QUIP-RS (excessive hobbies-punding and dopamine dysregulation syndrome) between groups. The total QUIP-RS scores is 0-112. Higher values represent a worse outcome.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 29 | -0.24 | -12 to 4 |
| Placebo | 30 | 0.43 | 0 to 8.00 |
C-SSRS is a suicidal ideation rating scale. The change may be the answers to the questions of C-SSRS. There are five questions and have binary responses (yes/no). Assign a score of 1 if answer yes and score of 0 if no . Higher values represent a worse outcome.The mximum score is 5.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| CBD Cannabis Extract Oral Solution | 30 | 0 | 0 to 0 |
| Placebo | 30 | 0 | 0 to 0 |
Between 9/5/2018 and 1/4/2022, 74 participants were screened, 61 randomized and 31 assigned to the CBD/THC drug and 30 to placebo. 13 participants were excluded: 8 participants not meeting inclusion criteria, and 5 declined to participate after screening.
| Milestone | CBD Cannabis Extract Oral Solution | Placebo |
|---|---|---|
| STARTED | 31 | 30 |
| COMPLETED | 30 | 30 |
| NOT COMPLETED | 1 | 0 |
| Event | System | Groups: affected / at risk |
|---|---|---|
| pneumonia | Respiratory, thoracic and mediastinal disorders | CBD Cannabis Extract Oral Solution: 1 / 31 · Placebo: 0 / 30 |
| Event | System | Groups: affected / at risk |
|---|---|---|
| dizziness | Nervous system disorders | CBD Cannabis Extract Oral Solution: 18 / 31 · Placebo: 6 / 30 |
| feeling of relaxation | Nervous system disorders | CBD Cannabis Extract Oral Solution: 13 / 31 · Placebo: 7 / 30 |
| fatigue | Nervous system disorders | CBD Cannabis Extract Oral Solution: 10 / 31 · Placebo: 6 / 30 |
| decreased concentration | Nervous system disorders | CBD Cannabis Extract Oral Solution: 10 / 31 · Placebo: 4 / 30 |
| headache | Nervous system disorders | CBD Cannabis Extract Oral Solution: 9 / 31 · Placebo: 10 / 30 |
| somnolence | Nervous system disorders | CBD Cannabis Extract Oral Solution: 8 / 31 · Placebo: 8 / 30 |
| feeling abnormal | Nervous system disorders | CBD Cannabis Extract Oral Solution: 8 / 31 · Placebo: 2 / 30 |
| feeling drunk | Nervous system disorders | CBD Cannabis Extract Oral Solution: 7 / 31 · Placebo: 2 / 30 |
| nausea | Gastrointestinal disorders | CBD Cannabis Extract Oral Solution: 6 / 31 · Placebo: 3 / 30 |
| confusion | Nervous system disorders | CBD Cannabis Extract Oral Solution: 5 / 31 · Placebo: 1 / 30 |
| thinking abnormal | Nervous system disorders | CBD Cannabis Extract Oral Solution: 5 / 31 · Placebo: 0 / 30 |
| disorientation | Nervous system disorders | CBD Cannabis Extract Oral Solution: 4 / 31 · Placebo: 0 / 30 |
Eligibility
primary outcomes
Time frame: From baseline to the end of 2.5 mg/kg/day of CBD, through 3 weeks
Movement Disorders Society-Unified Parkinson's disease rating scale(MDS UPDRS) Part III assesses the motor signs of PD. There are 33 scores based on 18 items, several with right, left or other body distribution scores.Each question is anchored with five responses that are linked to commonly accepted clinical terms: 0=normal, 1=slight, 2=mild, 3=moderate, and 4=severe. The possible change may be the scores of the total 33 scores. Scores ranges 0 -132. Higher values represent a worse outcome.
secondary outcomes
Time frame: Every 3-5 days at each dose level, assessed up to 3 weeks
Adverse events (AEs) are collected at each dose level. AEs collection include Serious Adverse Events (SAE), withdrawal symptoms and common AEs. SAE is an undesirable medical occurrence that results in death, or life-threatening, or inpatient hospitalization or prolongation of existing hospitalization or significant disability or incapacity or in a congenital anomaly/birth defect. Withdrawal and common AEs include headache, anxiety, nausea/vomiting, tremor, chills, decreased concentration, increased concentration, agitation, irritability, sleep disturbances, mood changes, somnolence, fatigue, anorexia, appetite changes, weight loss or gain, diarrhea, convulsion, abdominal pain, weakness, fever and other unexpected AEs. All of the these AEs will be recorded and counted.
Time frame: Baseline; at the end of 2.5 mg/kg/day; and every 3-5 days at each dose level, through 3 weeks.
Liver function tests will be performed and evaluated at each clinic visit from baseline through 3 weeks. The result is reported as the number of participants that had a clinically significant change in the values of the liver function test, including aspartate aminotransferase (AST), Alanine transaminase (ALT), Gamma-glutamyl transferase (GGT), Alkaline phosphatase (Alk Phos), Total Bilirubin (TB).
Time frame: Baseline; at the end of 2.5 mg/kg/day; and every 3-5 days at each dose level, through 3 weeks.
Liver function impairment will be evaluated and then related to adverse events and documented at each clinic visit. The change may be the frequency and severity of liver function impairment related AEs, including nausea/vomiting, diarrhea, abdominal pain, fatigue, weakness, chills, appetite changes, weight loss or gain, fever, etc.
Time frame: Baseline; at the end of 2.5 mg/kg/day, through 3 weeks
Standing systolic blood pressure measurements will be assessed through 3 weeks. The change may be the value of systolic blood pressure.
Time frame: Baseline; at the end of 2.5 mg/kg/day, through 3 weeks
The change may be Heart rate (beat/minute) while standing.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be weight in kilograms or lbs.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be temperature in Fahrenheit degree
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The result is reported as the number of participants that had a clinically significant change in the physical exam findings, including allergic immunologic, cardiovascular, constitutional symptoms, ENT, endocrine, eyes, gastrointestinal, genitourinary, hematologic, integumentary, musculoskeletal, neurological, psychiatric, respiratory and other symptoms clinical significant findings.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The result is reported as the number of participants that had a clinically significant change in the general neurological exam clinical significant findings, including cranial nerves, motor strength, sensation, reflexes, gait, and other movements.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The result is reported as the number of participants that had a clinically significant change in the EKG.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The result is reported as the number of participants that had a clinically significant change in the values of Hematology parameters, including RBC, WBC, HB, PLT, et al.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The result is reported as the number of participants that had a clinically significant change in the values of the Chemistry profile, including BUN, CR, Electrolyte, glucose, liver function, etc.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild cognitive dysfunction. The change may be the scores of MoCA, which is ranging from 0-30. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Wechsler test for Adult Reading. Wechsler Test of Adult Reading (WTAR) - Word reading tests are an established method of establishing a premorbid estimate of verbal intellectual functioning, which will serve as an estimate of premorbid cognitive reserve. The WTAR comprises 50 words with irregular pronunciations that participants read aloud. The raw score can be transformed to an age-adjusted standard score, which is used to predict IQ (M = 100; SD = 15). Scores higher means better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change are the scores of Grooved Pegboard Test for the dominant affected hand. Manipulative dexterity, including finger speed, is assessed. Scoring is the time it took the participant to complete the task. Start the clock once the participant starts and stop it once the task has been completed. If after five minutes the participant has not completed the pegboard, stop the participant. The score the higher the worse.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Intellectual functioning estimate, Symbol digit modalities test (SDMT). The SDMT is a measure of processing speed and working memory that has proven to be sensitive to cognitive impairment in MS that has both oral and written trials (only the oral trial will be administered given the anticipated difficulty patients will have with tremor). Participants are presented with a key at the top of a page pairing unique symbols with single digits. Participants are required to provide the correct digit with symbols that are presented on the rest of the page. The score is the number of correctly coded items from 0-110. The number of correct responses provided in 90 seconds on the oral trial is recorded. Scores range 0-110 items. The higher the score the better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Intellectual functioning estimate, Paced auditory serial addition test. Paced Auditory Serial Addition Test (PASAT) - The PASAT is a more complex measure of processing speed and working memory in which a series of digits is presented to participants at varying intervals (i.e., 2 seconds, 3 seconds). Participants must add each digit to the immediately preceding digit for the duration of each trial. The number of correct responses for each trial is recorded. The score for the PASAT is the total number correct out of 60 possible answers. The higher, the better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Intellectual functioning estimate, Controlled oral word association test (COWAT). The COWAT is a measure of speeded verbal fluency and word retrieval in which participants are asked to say as many words as they can that begin with each of three letters for 60 seconds. The total number of words generated across all three trials is recorded. The higher, the better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Intellectual functioning estimate, Hopkins verbal learning test-revised. Hopkins Verbal Learning Test-Revised (HVLT-R) - The HVLT-R is a measure of verbal learning and memory in which participants are asked to learn a 12-item word list over three trials (total immediate learning). When scoring, the three leaning trials are combined to calculate a total recall score. Score ranges 0-36. The higher, the better. The outcoe measure is reporting the change from baseline in the total leaning score across all three trials.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed recall trial. The participant is asked to recall as many words as they can 20-25 minutes after being presented the word list. The range is 0-12; the higher, the better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Intellectual functioning estimate, Hopkins verbal learning test-revised. Hopkins Verbal Learning Test-Revised (HVLT-R) is a measure of verbal learning and memory in which participants are asked to learn a 12-item word list over three trials (total immediate learning). Delayed recognition trials is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, and 6 semantically unrelated. Retention % = percentage retained or delayed recall divided by better score on trial 2 or 3. Range 0-1. The higher, the better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Intellectual functioning estimate, Judgment of line orientation. Judgment of Line Orientation (JOLO) - The JOLO is test of visuospatial functioning which measures a person's ability to match the angle and orientation of lines in space. Patients are asked to match two angled lines to a set of 11 lines that are arranged in a semicircle and separated 18 degrees from each other. Score ranges 0-30. The higher, the better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The change may be the scores of Semantic verbal fluency. Semantic Verbal Fluency - Semantic Verbal fluency is a measure of speeded verbal fluency and word retrieval in which participants are asked to say as many animal names/fruits and vegetables for 60 seconds. The total number of words generated across all three trials is recorded. The higher the score is, the better.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Comprised of 8 items which has five response options. Anxiety short form - is component of the Neurol-QOL (Quality of Life in Neurological Disorders) Measurement System, which is a collaborative effort of the National Institute of Neurological Disorders and Stroke and a number of partnering institutions. This measurement system was designed to be responsive to the needs of researchers in a variety of neurological disorders and to facilitate comparisons of data across clinical trials in different diseases. The short form is comprised of eight items that were selected from the respective item bank. Items have five response options (e.g., 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always). Respondents generally can answer five questions per minute. The change may be the total scores of the 8 items. Higher values represent a worse outcome. Scores range 8-40.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Valid and reliable scale to provide a means of assessing neuropsychiatric symptoms and psychopathology of patients. The change may be the scores of NPI. Neuropsychiatric Inventory (NPI) - is a valid and reliable scale. It was developed to provide a means of assessing neuropsychiatric symptoms and psychopathology of patients with Alzheimer's disease and other neurodegenerative disorders. It has proven to be sensitive to change and has been employed to capture treatment related behavioral. The NPI is administered to a caregiver/significant other who has detailed knowledge of the participant's behavior. Higher values represent a worse outcome. Score ranges 0-12.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Scales for Outcomes in Parkinson's disease (SCOPA)sleep - is a valid, reliable, short scale for assessing daytime sleepiness (DS) and nighttime sleep problems (NS) in patients with PD. The DS sub scale evaluates daytime sleepiness and includes six items with four response options, ranging from 0 (never) to 3 (often). The score ranges 0-18. The higher the worse. The other
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Comprised of 8 items which item has five response options. Depression short form - is a component of the Neurol-QOL (Quality of Life in Neurological Disorders) Measurement System, which is a collaborative effort of the National Institute of Neurological Disorders and Stroke and a number of partnering institutions. This measurement system was designed to be responsive to the needs of researchers in a variety of neurological disorders and to facilitate comparisons of data across clinical trials in different diseases. The short form is comprised of eight items that were selected from the respective item bank. Items have five response options (e.g., 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always). Respondents generally can answer five questions per minute. The change may be the scores of the total 8 items. Score ranges 0-40. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Comprised of 8 items which item has 5 response options. Emotional and behavioral dyscontrol short form - is a component of the Neurol-QOL Measurement System, which is a collaborative effort of the National Institute of Neurological Disorders and Stroke and a number of partnering institutions. This measurement system was designed to be responsive to the needs of researchers in a variety of neurological disorders and to facilitate comparisons of data across clinical trials in different diseases. The short form is comprised of eight items that were selected from the respective item bank. Items have five response options (e.g., 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always). Respondents generally can answer five questions per minute. The change may be the total scores of the 8 items. Score ranges 0-40. Higher values represent a worse outcome.
Time frame: Pre- and 3 hours post- dose at baseline visit
Is a quick and easy way to assess how the participant is feeling. The change may be the scores of the scale 3 hours after dosing compared to pre-dosing. Stanford Sleepiness Scale (SSS): The Stanford Sleepiness Scale is a quick and easy way to assess how alert the participant is feeling. SSS is validated and probably the most widely used instrument for the assessment of participant's sleepiness. Score ranges 0-7. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Assess how much a person hurts. The change may be the score of the short form. Pain Intensity 3a short form - components of the Patient Reported Outcome Measurement Information System (PROMIS), which was developed by the NIH to provide a standardized metric for measuring physical, mental, and social health across chronic diseases. PROMIS instruments were developed using item response theory and have been tested in more than 20,000 individuals drawn from the general US population. The Pain Intensity instrument assesses how much a person hurts. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Each question has five response options ranging in value from one to five. Score ranges 0-15. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Self-reported consequences of pain on relevant aspects of one's life. The change may be the scores of the short form. The Pain Interference instrument measures the self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Each question has five response options ranging in value from one to five. Score ranges 0-20. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Self-report 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity. The change may be the total scores of the 9 items, ranging from 9-63. Higher values represent worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Movement Disorder Society Unified Parkinson Disease Rating Scale. There are four parts, non-motor experiences of daily living, motor experiences of daily living, motor examination, and motor complications. The change may be the total scores of the four parts. Total score ranges 0-260. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
To evaluate involuntary movements often associated with treated PD. The change may be the total scores of the scale, including historical sub-score (0-60) and objective sub-score (0-44). The total score is historical sub score plus objective sub score, ranged from 0- 104. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
The Timed Up \& Go (TUG) test is a physical performance measure in which the ability to rise up from a seated chair position, walk 3m, turn, walk back, and sit down is timed. This measure is useful in an outpatient setting, because it requires only a few minutes, is easy to administer, and requires little equipment. Importantly, the TUG test is highly correlated with functional mobility, gait speed, and falls in older adults. The change may be the time duration (seconds) of performing the task. The higher, the worse.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
International restless legs syndrome (IRLS) study group rating scale for restless legs syndrome. The change may be the scores of the IRLS, ranged from 0-40. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
REM sleep behavior disorder screening questionnaire (RBDSQ). The change may be the total scores of RBDSQ. REM sleep behavior disorder screening questionnaire (RBDSQ) - is a 10-item, patient self-rating instrument assessing the participant's sleep behavior with short questions that have to be answered by either "yes" or "no". Items 1 to 4 address the frequency and content of dreams and their relationship to nocturnal movements and behavior. Item 5 asks about self-injuries and injuries of the bed partner. Item 6 consists of four sub items assessing nocturnal motor behavior more specifically, e.g., questions about nocturnal vocalization, sudden limb movements, complex movements, or bedding items that fell down. Items 7 and 8 deal with nocturnal awakenings. Item 9 focuses on disturbed sleep in general and item 10 on the presence of any neurological disorder. The maximum total score of the RBDSQ is 13 points. Score ranges 0-13 points. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
A validated self-administered questionnaire consisting of 7 questions on a 5-point Likert scale. The change may be the scores of the scale, ranged from 0-35. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
A reliable valid responsive acceptable and feasible tool for assessment of quality of life in PD, including 39 multiple-choice items covering 8 dimensions: mobility (#1-10), activities of daily living (#11-16), emotional well-being (#17-22), stigma (#23-26), social support (#27-29), cognition (#30-33), communication (#34-36), and bodily discomfort (#37-39). 5-point ordinal scoring system: 0=never, 1= occasionally, 2=sometimes, 3=often, 4=always. The change may be the total scores of PDQ-39, ranged from 0-156. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Consists of 2 pages-the EuroQol-5 Dimension-5 level (EQ-5D-5L) descriptive system and the EuroQol (EQ) Visual analogue scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The VAS records the patient's self-rated health on a vertical visual analogue-scale, where the endpoints are labelled the best health you can imagine and the worst health you can imagine. The change may be the scales of EQ-5D. Score ranges 11111-55555. The higher, the worse.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Difference in Proportion of participants that discontinue the study due to study drug intolerance. The change may be the number of patients dropped out.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Rest tremor amplitude and constancy of rest tremor scores in MDS UPDRS. The change may be the sum scores of 3.17 and 3.18. Score ranged from 0-24. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Patient's tremor experience. The change may be the scores of item 2.10. Score ranged from 0-4. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Postural tremor of the hands and kinetic tremor of the hand. The change may be the sum scores of item 3.15 and 3.16. Score ranged from 0-16. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Rigidity sub scores in MDS UPDRS. The change may be the sub scores of rigidity related item in MDS UPDRS (item 3.3). Score ranged from 0-20. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Bradykinesia sub scores in MDS UPDRS. The change may be the sub scores of bradykinesia related items in MDS UPDRS, including items 3.4-3.8, and 3.14. The scores ranged from 0-44. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Axial sub scores in MDS UPDRS. The change may be the sub scores of axial related items in MDS UPDRS, including items 3.9, 3.13, 3.10, 3.11, and 3.12. The sub scores ranged from 0-20. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Bulbar sub scores in MDS UPDRS (item 3.1 and 3.2). The change may be the sub scores of bulbar related items in MDS UPDRS, ranged from 0-8. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Insomnia Severity Index (ISI): ISI is a verified seven-item self-report questionnaire assessing the nature, severity, and impact of insomnia. A five-point Likert scale is used to rate each item (e.g., 0=no problem; 4=very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28). A total score ranging from 0 to 28. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
To measure the quality and patterns of sleep in adults. It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. The change may be the total scores, ranged from 0 to 42. The higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Dermatology quality of life index. The change may be the scores of the questionnaire. The scoring of each question is as follows: very much=3, a lot =2, a little=1, not at all=0, not relevant =0. Question 7, prevented work or studying =3. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Dermatology photography evaluation. The change in number of participants with a presence of seborrheic dermatitis from baseline to final visit. Dermatology photography: take a picture of the central face, as this is the most common area of seborrhea, and send it, with appropriate privacy safeguards, to dermatologists, Dr. Robert Dellavalle, MD., and Dr. Andrea Steel.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Validated 30-item scale for the assessment of NMS in PD. Each symptom scored with respect to severity (0=none, 1=mild, 2=moderate, 3=severe), frequency (1=rarely, 2=often, 3=frequent, 4=very frequent). Each NMSS item score is calculated by multiplying the severity and frequency score. The final score is the sum of the total 30-item scores. The change may be the total scores of NMSS, ranged from 0 to 360. The higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Scales for Outcomes in Parkinson's disease (SCOPA) sleep DS subscale is a valid, reliable, short scale for assessing daytime sleep problems (DS) in patients with PD. The sub scale includes six items with four response options, ranging from 0 (never) to 3 (often). The score ranges 0-18. The higher the worse.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Scales for Outcomes in Parkinson's disease (SCOPA) sleep NS subscale - is a valid, reliable, short scale for assessing nighttime sleep problems (NS) in patients with PD. The NS sub scale includes five items with four response options, ranging from 0 (never) to 3 (often). The score ranges 0-15. The higher the worse.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Modified Dysfunctional Beliefs and Attitudes about Sleep Questionnaire (DBAS-16): A validated self-reported questionnaire designed to identify and assess various sleep/insomnia-related cognitions (e.g., beliefs, attitudes, expectations, appraisals, attributions). range is 0-160; the higher numbers are worse.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
WASO, the total number of minutes that a person is awake after having initially fallen asleep; higher numbers are worse.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
Interleukin 6 is an inflammatory cytokine, and is measured in the blood. Whole bold was collected into tubes containing anticoagulant; tubes were inverted gently 3-4 times. Blood was allowed to clot at room temperature for 30 to 45 min, centrifuged at 1,000 x g for 15 min at 4°C and serum was transferred to a clean polypropylene tube. To completely remove platelets and precipitates, the tubes were centrifuge again at 10,000 x g for 10 min at 4°C. Processed samples were stored at -80°F, and cytokine levels measured using the Bio-Plex ProTM Human Cytokine Assay.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
To measure severity of symptoms and support a diagnosis of impulse control disorders and related disorders in PD. The result is the difference of the change of the total scores of QUIP-RS (excessive hobbies-punding and dopamine dysregulation syndrome) between groups. The total QUIP-RS scores is 0-112. Higher values represent a worse outcome.
Time frame: From baseline to the end of 2.5 mg/kg/day, assessed up to 3 weeks
C-SSRS is a suicidal ideation rating scale. The change may be the answers to the questions of C-SSRS. There are five questions and have binary responses (yes/no). Assign a score of 1 if answer yes and score of 0 if no . Higher values represent a worse outcome.The mximum score is 5.
Publications
| dry mouth |
| General disorders |
| CBD Cannabis Extract Oral Solution: 4 / 31 · Placebo: 1 / 30 |
| fall | General disorders | CBD Cannabis Extract Oral Solution: 4 / 31 · Placebo: 3 / 30 |
| increased concentration | Nervous system disorders | CBD Cannabis Extract Oral Solution: 4 / 31 · Placebo: 1 / 30 |
| weakness | General disorders | CBD Cannabis Extract Oral Solution: 4 / 31 · Placebo: 1 / 30 |
| agitation | Nervous system disorders | CBD Cannabis Extract Oral Solution: 3 / 31 · Placebo: 1 / 30 |
| elevated mood | Nervous system disorders | CBD Cannabis Extract Oral Solution: 3 / 31 · Placebo: 3 / 30 |
| diarrhea | Gastrointestinal disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 4 / 30 |
| anorexia | Metabolism and nutrition disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 3 / 30 |
| anxiety | Nervous system disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 3 / 30 |
| insomnia | Nervous system disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 3 / 30 |
| abdominal pain | Gastrointestinal disorders | CBD Cannabis Extract Oral Solution: 1 / 31 · Placebo: 3 / 30 |
| sleep disturbance | Nervous system disorders | CBD Cannabis Extract Oral Solution: 1 / 31 · Placebo: 2 / 30 |
| weight loss | General disorders | CBD Cannabis Extract Oral Solution: 1 / 31 · Placebo: 2 / 30 |
| cold | Respiratory, thoracic and mediastinal disorders | CBD Cannabis Extract Oral Solution: 0 / 31 · Placebo: 2 / 30 |
| cough | Respiratory, thoracic and mediastinal disorders | CBD Cannabis Extract Oral Solution: 0 / 31 · Placebo: 2 / 30 |
| depression | Nervous system disorders | CBD Cannabis Extract Oral Solution: 0 / 31 · Placebo: 2 / 30 |
| constipation | Gastrointestinal disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 0 / 30 |
| chills | General disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 0 / 30 |
| increased appetite | Metabolism and nutrition disorders | CBD Cannabis Extract Oral Solution: 4 / 31 · Placebo: 0 / 30 |
| irritability | Psychiatric disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 0 / 30 |
| urinary tract infection | Renal and urinary disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 0 / 30 |
| vomiting | Gastrointestinal disorders | CBD Cannabis Extract Oral Solution: 2 / 31 · Placebo: 0 / 30 |